{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:45:35Z","timestamp":1790840735630,"version":"4.1.0"},"reference-count":63,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Aspirin inhibits platelet function by irreversibly inhibiting the synthesis of thromboxane A2 (TxA2). Aspirin, at low doses, is widely used for cardiovascular prevention. Gastrointestinal discomfort, mucosal erosions\/ulcerations and bleeding are frequent complications of chronic treatment. To reduce these adverse effects, different formulations of aspirin have been developed, including enteric-coated (EC) aspirin, the most widely used aspirin formulation. However, EC aspirin is less effective than plain aspirin in inhibiting TxA2 production, especially in subjects with high body weight. The inadequate pharmacological efficacy of EC aspirin is mirrored by lower protection from cardiovascular events in subjects weighing &gt;70 kg. Endoscopic studies showed that EC aspirin causes fewer erosions of the gastric mucosa compared to plain aspirin (which is absorbed in the stomach) but causes mucosal erosions in the small intestine, where it is absorbed. Several studies demonstrated that EC aspirin does not reduce the incidence of clinically relevant gastrointestinal ulceration and bleeding. Similar results were found for buffered aspirin. Although interesting, the results of experiments on the phospholipid-aspirin complex PL2200 are still preliminary. Considering its favorable pharmacological profile, plain aspirin should be the preferred formulation to be used for cardiovascular prevention.<\/jats:p>","DOI":"10.3390\/jcdd10040137","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T02:34:54Z","timestamp":1679625294000},"page":"137","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacological Efficacy and Gastrointestinal Safety of Different Aspirin Formulations for Cardiovascular Prevention: A Narrative Review"],"prefix":"10.3390","volume":"10","author":[{"given":"Bianca","family":"Clerici","sequence":"first","affiliation":[{"name":"Divisione di Medicina Generale II, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milano, Via Di Rudin\u00ec 8, 20142 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-4534","authenticated-orcid":false,"given":"Marco","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Fondazione Arianna Anticoagulazione, Via Paolo Fabbri 1\/3, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1073\/pnas.72.8.2994","article-title":"Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides","volume":"72","author":"Hamberg","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","first-page":"2245","article-title":"Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis [published correction appears in JAMA","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Steering Committee of the Physicians Health Study Research Group (1989). Final report of the aspirin component of the outgoing physicians health study. N. Engl. J. Med., 321, 129\u2013135.","DOI":"10.1056\/NEJM198907203210301"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/S0002-9270(00)01040-6","article-title":"Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin","volume":"95","author":"Mellemkjaer","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","article-title":"Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis","volume":"321","author":"Derry","year":"2000","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1093\/eurheartj\/ehp256","article-title":"Gastrointestinal bleeding in high risk survivors of myocardial infarction: The VALIANT Trial","volume":"30","author":"Moukarbel","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00535-014-1028-x","article-title":"Small bowel injury in low-dose aspirin users","volume":"50","author":"Endo","year":"2015","journal-title":"J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1345\/aph.18325","article-title":"Risk of gastric injury with enteric- versus nonenteric-coated aspirin","volume":"36","author":"Banoob","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jps.3030390108","article-title":"Effect of buffering agents on absorption of acetylsalicylic acid","volume":"39","author":"Paul","year":"1950","journal-title":"J. Amer Pharm. Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40262-021-01090-2","article-title":"Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation","volume":"61","author":"Angiolillo","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers","volume":"37","author":"Cox","year":"2006","journal-title":"Stroke"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2165\/00003088-198510050-00002","article-title":"Clinical significance of esterases in man","volume":"10","author":"Williams","year":"1985","journal-title":"Clin. Pharmacokinet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","article-title":"Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase","volume":"311","author":"Pedersen","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.12637","article-title":"Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action","volume":"12","author":"Patrignani","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_16","first-page":"51","article-title":"Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers","volume":"6","author":"Nagelschmitz","year":"2014","journal-title":"Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2165\/00003088-199121050-00006","article-title":"Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers","volume":"21","author":"Bochner","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1055\/s-0040-1714351","article-title":"Patients with Essential Thrombocythemia may be Poor Responders to Enteric-Coated Aspirin, but not to Plain Aspirin","volume":"120","author":"Scavone","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJM195801302580503","article-title":"Comparison of buffered and unbuffered acetylsalicylic acid","volume":"258","author":"Batterman","year":"1958","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0002-9149(99)00324-0","article-title":"Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution","volume":"84","author":"Feldman","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11239-019-01933-7","article-title":"Pharmacokinetic\/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: Results of a randomized, crossover, bioequivalence study","volume":"48","author":"Angiolillo","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1161\/01.ATV.0000145980.39477.a9","article-title":"Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance","volume":"24","author":"Cattaneo","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0049-3848(80)90066-3","article-title":"Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects","volume":"17","author":"Patrono","year":"1980","journal-title":"Thromb. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V69.1.180.180","article-title":"Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs","volume":"69","author":"Reilly","year":"1987","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jacc.2005.06.058","article-title":"Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease","volume":"46","author":"Maree","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1111\/j.1538-7836.2010.03997.x","article-title":"The role of weight and enteric coating on aspirin response in cardiovascular patients","volume":"8","author":"Peace","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.112.117283","article-title":"Drug resistance and pseudoresistance: An unintended consequence of enteric coating aspirin","volume":"127","author":"Grosser","year":"2013","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/cpt.874","article-title":"Lack of Bioequivalence Among Low-dose, Enteric-coated Aspirin Preparations","volume":"103","author":"Cox","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jacc.2016.11.050","article-title":"Enteric Coating and Aspirin Nonresponsiveness in Patients with Type 2 Diabetes Mellitus","volume":"69","author":"Bhatt","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00228-022-03391-2","article-title":"The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: Prospective cohort study: Results from the (ECASIS) study","volume":"78","author":"Elshafei","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cattaneo, M. (Haematologica, 2023). Aspirin in essential thrombocythemia: To whom? What formulation? What regimen?, Haematologica, Epub ahead of print.","DOI":"10.3324\/haematol.2022.281388"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: Analysis of individual patient data from randomised trials","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"(1998). Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council\u2019s General Practice Research Framework. Lancet, 351, 233\u2013241.","DOI":"10.1016\/S0140-6736(97)11475-1"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2036.1999.00588.x","article-title":"Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions","volume":"13","author":"Dammann","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJM198007173030305","article-title":"Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa","volume":"303","author":"Lanza","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.1991.tb05616.x","article-title":"Aspirin-induced gastric mucosal damage: Prevention by enteric-coating and relation to prostaglandin synthesis","volume":"32","author":"Hawthorne","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2036.1999.00470.x","article-title":"Protection of human gastric mucosa against aspirin\u2014Enteric coating or dose reduction?","volume":"13","author":"Cole","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1472-8206.2000.tb00404.x","article-title":"Gastroduodenal tolerability of medium dose enteric-coated aspirin: A placebo controlled endoscopic study of a new enteric-coated formulation versus regular formulation in healthy volunteers","volume":"14","author":"Blondon","year":"2000","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_44","first-page":"314","article-title":"Endoscopic comparison of three aspirin preparations and placebo","volume":"15","author":"Petroski","year":"1993","journal-title":"Clin. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(80)90282-2","article-title":"Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man","volume":"2","author":"Hoftiezer","year":"1980","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ajg.2010.436","article-title":"Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: A randomized clinical trial","volume":"106","author":"Cryer","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","article-title":"Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product","volume":"348","author":"Kelly","year":"1996","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"De Abajo, F.J., and Garc\u00eda Rodr\u00edguez, L.A. (2001). Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin. Pharmacol., 1.","DOI":"10.1186\/1472-6904-1-1"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.0306-5251.2001.01476.x","article-title":"Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies","volume":"52","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00535-009-0040-z","article-title":"Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: The experience of two medical centers in capsule endoscopy","volume":"44","author":"Endo","year":"2009","journal-title":"J. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.dld.2012.05.016","article-title":"Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy","volume":"44","author":"Endo","year":"2012","journal-title":"Dig. Liver Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.2147\/IJGM.S326929","article-title":"Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review","volume":"14","author":"Kedir","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/gut.38.1.11","article-title":"Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers","volume":"38","author":"Murray","year":"1996","journal-title":"Gut"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cgh.2007.12.018","article-title":"Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin","volume":"6","author":"Dieleman","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.jacc.2015.12.068","article-title":"Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy","volume":"67","author":"Vaduganathan","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.3748\/wjg.v21.i17.5382","article-title":"Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries","volume":"21","author":"Mo","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/joim.12103","article-title":"Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding\u2014A cohort study of the effects of proton pump inhibitor use patterns","volume":"274","author":"Hedberg","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mo, C., Sun, G., Wang, Y.Z., Lu, M.L., and Yang, Y.S. (2015). PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131558"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000489165","article-title":"H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review","volume":"140","author":"Almufleh","year":"2018","journal-title":"Cardiology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bpg.2012.01.011","article-title":"Risk factors for gastrointestinal bleeding associated with low-dose aspirin","volume":"26","author":"Valkhoff","year":"2012","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.109.853069","article-title":"New P2Y(12) inhibitors","volume":"121","author":"Cattaneo","year":"2010","journal-title":"Circulation"}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/4\/137\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:01:32Z","timestamp":1760122892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/4\/137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcdd10040137"],"URL":"https:\/\/doi.org\/10.3390\/jcdd10040137","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}